2024

Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h
Becher N, Toennis T, Bertaglia E, Blomstrom Lundqvist C, Brandes A, Cabanelas N, Calvert M, Camm A, Chlouverakis G, Dan G, Dichtl W, Diener H, Fierenz A, Goette A, de Groot J, N L Hermans A, Lip G, Lubiński A, Marijon E, Merkely B, Mont L, Ozga A, Rajappan K, Sarkozy A, Scherr D, Schnabel R, Schotten U, Sehner S, Simantirakis E, Vardas P, Velchev V, Wichterle D, Zapf A, Kirchhof P
EUR HEART J. 2024;45(10):837-849.

Anticoagulation in Patients With Device-Detected Atrial Fibrillation With and Without a Prior Stroke or Transient Ischemic Attack: The NOAH-AFNET 6 Trial
Diener H, Becher N, Sehner S, Toennis T, Bertaglia E, Blomstrom-Lundqvist C, Brandes A, Beuger V, Calvert M, Camm A, Chlouverakis G, Dan G, Dichtl W, Fierenz A, Goette A, de Groot J, Hermans A, Lip G, Lubinski A, Marijon E, Merkely B, Mont L, Nikorowitsch J, Ozga A, Rajappan K, Sarkozy A, Scherr D, Schnabel R, Schotten U, Simantirakis E, Vardas P, Wichterle D, Zapf A, Kirchhof P
J AM HEART ASSOC. 2024;13(17):.

Current developments of the estimand concept
Fierenz A, Zapf A
PHARM STAT. 2024 [Epub ahead of print].

Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial
Lip G, Nikorowitsch J, Sehner S, Becher N, Bertaglia E, Blomstrom-Lundqvist C, Brandes A, Beuger V, Calvert M, Camm A, Chlouverakis G, Dan G, Dichtl W, Diener H, Fierenz A, Goette A, de Groot J, Hermans A, Lubinski A, Marijon E, Merkely B, Mont L, Ozga A, Rajappan K, Sarkozy A, Scherr D, Schnabel R, Schotten U, Simantirakis E, Toennis T, Vardas P, Wichterle D, Zapf A, Kirchhof P
EUR HEART J. 2024;45(19):1733-1737.

Clinical effectiveness of patient-targeted feedback following depression screening in general practice (GET.FEEDBACK.GP): an investigator-initiated, prospective, multicentre, three-arm, observer-blinded, randomised controlled trial in Germany
Löwe B, Scherer M, Braunschneider L, Marx G, Eisele M, Mallon T, Schneider A, Linde K, Allwang C, Joos S, Zipfel S, Schulz S, Rost L, Brenk-Franz K, Szecsenyi J, Nikendei C, Härter M, Gallinat J, König H, Fierenz A, Vettorazzi E, Zapf A, Lehmann M, Kohlmann S
LANCET PSYCHIAT. 2024;11(4):262-273.

Prognostic Relevance of Ischemic Late Gadolinium Enhancement in Apparently Healthy Endurance Athletes: A Follow-up Study Over 5 years
Lund G, Leptin S, Ragab H, Sinn M, Fierenz A, Cavus E, Muellerleile K, Chen H, Erley J, Harms P, Kisters A, Starekova J, Adam G, Tahir E
SPORTS MED-OPEN. 2024;10(1):.

Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials
Schnabel R, Benezet-Mazuecos J, Becher N, McIntyre W, Fierenz A, Lee S, Goette A, Atar D, Bertaglia E, Benz A, Chlouverakis G, Birnie D, Dichtl W, Blomstrom-Lundqvist C, Camm A, Erath J, Simantirakis E, Kutyifa V, Lip G, Mabo P, Marijon E, Rivard L, Schotten U, Alings M, Sehner S, Toennis T, Linde C, Vardas P, Granger C, Zapf A, Lopes R, Healey J, Kirchhof P
EUR HEART J. 2024 [Epub ahead of print].

Letzte Aktualisierung aus dem FIS: 03.11.2024 - 23:35 Uhr